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Abstract
Background: Little is known about the relationship between types of healthcare providers and
outcomes in patients with epilepsy. This study compares the relative effects of provider type
(epileptologist vs. other neurologist) and pharmacologic treatment (newer vs. older antiepileptic
drugs) on seizure control in patients with epilepsy.
Methods: We conducted a retrospective study of patients with medication-resistant epilepsy.
Consecutive charts of 200 patients were abstracted using a standard case report form. For each
patient, data included seizure frequency and medication use prior to, and while being treated by an
epileptologist. Changes in seizure frequency were modeled using a generalized linear model.
Results: After transferring care from a general neurologist to specialized epilepsy center, patients
experienced fewer seizures (p < 0.001) and were more frequently seizure-free (p < 0.001). The
improved seizure control was not related to treatment with newer vs. older antiepileptic drugs (p
= 0.305).
Conclusion: Our findings suggest an association between subspecialty epilepsy care and improved
seizure control in patients with medication-resistant epilepsy. Further research should
prospectively determine whether patients with medication-resistant epilepsy would benefit from
being routinely referred to an epilepsy specialist.
Background
In recent discussions about health care cost and utiliza-
tion in the United States, several factors emerge as rea-
sons for cost escalation.[1,2] Among them are increased
use of specialty physicians instead of generalists, choice
of expensive procedures instead of investment in preven-
tive measures, high-cost of new technologies and phar-
maceuticals, aging of the population and increasing
health care and administrative costs.[3] The perceived
need for more specialists to provide increasingly com-
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liferation of specialists over the last 40 years as
demonstrated by the 22% reduction in the number of
primary care physicians (PCP; from 50% to 28%) despite
the concurrent increase of the total number of physicians
(from 250,000 to 650,000).[4] However, evidence
shows that the number of specialists does not always
lead to improved care. Based on studies of cancer, heart
disease, stroke, and self-related health appropriate sup-
ply of PCPs is thought to be associated with improved
health outcomes.[5] One study has documented a
reverse relationship between the overall quality of care
received by Medicare beneficiaries and the cost of care,
with this negative relationship being driven by the use of
intensive and costly care that crowded out the use of the
more effective preventive and general medical care.[6]
Another study found that although cardiologists
improved the outcome of patients with myocardial inf-
arction when compared to the care provided by non-car-
diologists, the best outcome was achieved when
cardiologists and generalists combined their efforts.[7] A
similar relationship has been shown in neurologic vs.
general medical care of patients with acute stroke; neuro-
logic care was more costly but led to substantially
improved outcomes.[8] One possible explanation for
this disparity between cost and quality of care is that
while costly care and procedures are overutilized, less
expensive measures, such as prevention, are underuti-
lized.[6,8]
Studies examining the relationship between quality of
care and specialized care in patients with epilepsy are lim-
ited. One recent investigation explored the impact of an
epilepsy clinic on seizure control in institutionalized
patients and found that treatment by an epileptologist led
to an overall favorable outcome; 55% of patients experi-
enced reduction in seizure frequency and 23% of them
became seizure-free.[9] Another small retrospective study
also found improved seizure control in patients referred
to an epilepsy center.[10] Considering multiple, potential
factors in the relationship between quality and cost of care
in patients with epilepsy, we conducted a retrospective
chart review study to determine what factors contribute to
seizure control in patients with epilepsy across various
clinical settings. Specifically, we aimed to compare the rel-
ative contribution of type of provider (epileptologist vs.
general neurologist) and pharmacologic treatment (newer
vs. older antiepileptic drugs, or AEDs) to the overall sei-
zure control in patients with medication-resistant epi-
lepsy. We hypothesized, based on previous research, that
patients managed by non-epileptologists would have
poorer seizure control than when they were subsequently
managed by epileptologists, and that this difference
would depend on the type of physician and not on the
choice of AED. [9-11]
Methods
Subjects
This retrospective observational study was approved by
the Institutional Review Board of the University of Cincin-
nati (consent requirement waived). All patients treated in
the outpatient clinic of the Cincinnati Epilepsy Center
between 11/1/06 and 8/31/07 were eligible to participate
in the study. Overall, we enrolled 200 patients, with bal-
anced numbers of patients from different clinical settings
to eliminate the possibility of the clinical setting con-
founding the results – 100 institutionalized patients (e.g.,
nursing home, group home, or independent supervised
living) and 100 non-institutionalized patients.
Data collection
All potential study subjects were identified by a study
coordinator who was blinded to the overall goals of the
study. We first identified institutionalized patients and
then non-institutionalized patients matched for age and
gender from the group of patients evaluated by the same
physician on the same day. Next, the selected charts were
reviewed and abstracted by a study physician. Charts were
abstracted by a single investigator (AYR) using a standard-
ized case report form and data dictionary with explicit,
pre-specified data definitions. Disease- and treatment-spe-
cific data including type of epilepsy, AED therapy before
and during the treatment in the epilepsy center, duration
of epilepsy, outcomes (as defined below), and complica-
tions of treatment were extracted. In cases where the chart
entry was not clear, the physician responsible for the
patient was directly contacted with questions and/or a
request for additional records (approximately 5% of the
charts). Clinical notes were also reviewed for the clini-
cian's impression regarding response to therapy and to
ascertain side effects of AED treatment. Approximately
25% of charts were selected at random and re-reviewed by
another investigator (JPS) to confirm the accuracy of the
collected data.
Data definitions
For the purpose of this study, we defined epileptologist as
any neurologist who had undergone specific training in
the diagnosis and management of epilepsy (i.e., com-
pleted at least one year of epilepsy/clinical neurophysiol-
ogy fellowship) and whose scope of practice was focused
on the management of patients with epilepsy at the time
of the study. All other neurologists were considered non-
epilepsy (or other) physicians.
We defined the following seizure outcome variables:
1) Baseline seizure frequency: Seizure frequency at the time
of the initial visit in the epilepsy center was defined as the
average number of seizures per month at the time of the
first visit spanning the 3 months prior to the visit; expand-Page 2 of 6
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match the "current mean monthly seizure frequency" var-
iable was impractical as the majority of charts did not con-
tain such information.
2) Current mean monthly seizure frequency: Defined as
number of seizures per month averaged over 12 months
prior to the most current visit. This variable was treated
either as categorical (presence or absence of seizures, also
called the "seizure-freedom" variable) or continuous (aver-
age number of seizures per month).
Duration of epilepsy was defined as the difference
between the age at epilepsy onset and the age at the last
visit; two additional epilepsy duration treatment variables
were defined: the duration of treatment by an epileptolo-
gist, measured as the number of years the patient was fol-
lowed in the Cincinnati Epilepsy Center, and the duration
of treatment by a non-epileptologist, measured as the
number of years the patient was treated by a general neu-
rologist(s) for epilepsy before referral to the epilepsy
center. Some patients either self-referred or were referred
by their primary care specialist, but all patients included
in this study were followed by a general neurologist prior
to their first visit to the epilepsy center.
Medication outcome variables were defined as the
number of "older AEDs" (bromides, barbiturates, benzo-
diazepines, phenytoin/other hydantoins, carbamazepine
immediate release, valproic acid, succinamides) and
"newer AEDs" (carbamazepine extended release formula-
tions, felbamate, gabapentin, lamotrigine, levetiracetam,
oxcarbazepine, pregabalin, tiagabine, topiramate, zonisa-
mide, investigational drugs) ever used. Carbamazepine
extended release was included in the "newer AEDs" cate-
gory as this formulation was introduced to the market
along with the other "newer AEDs"; this AED has been
shown to be more efficacious and causing less side effects
than the immediate release carbamazepine.[12] Other
medication variables included the number and type of
AEDs, and whether they were prescribed by an epileptol-
ogist or other neurologist. In cases when it was not clear
who prescribed the AED or when the AED was initiated by
one physician but adjusted by the epileptologist, both
were credited with the use of the particular AED. Finally,
we broadly defined AED side effects as the presence or
absence of side effects leading to AED discontinuation.
Data analyses
Data were initially characterized using descriptive statis-
tics (means and standard deviations or frequencies and
percentages as appropriate). We compared between base-
line and the most current visits using Fisher's Exact test for
categorical data, and the Wilcoxon Signed-Rank test for
continuous data. We modeled the effect of provider type
and medication use on change in seizure frequency using
a generalized linear model. No adjustment for covariates
or multiple comparisons was attempted due to the explor-
atory nature of the study (see below). All data manage-
ment and analyses were performed using SPSS V. 15.0
(SPSS Inc., Chicago, IL, USA), the significance level was
set to 5% (α = 0.05) for all analyses.
Results
Twenty-two subjects were excluded from analyses because
they were followed by an epileptologist for less than 1
year, and the current mean monthly seizure frequency
could therefore not be assessed. Demographic and clinical
characteristics of the included subjects are presented in
Table 1. Overall, the median age for the studied popula-
tion was 43 years; 45.5% of patients were female. Approx-
imately 14% of patients were black. The median age of
epilepsy onset was 10 years and the median duration was
30.5 years. The epilepsy diagnosis distribution was similar
to major epidemiological studies and included 34.8%
patients with generalized epilepsies (idiopathic and
symptomatic combined) and 57.3% of patients with focal
onset epilepsies.[13] In approximately 7.9% of patients it
was not clear whether they had focal or generalized epi-
lepsy onset. The treatment by epileptologists was shorter
than the treatment by other physicians (6 years vs. 22
years). Despite that, more patients achieved seizure free-
dom while treated by epileptologists (26.4% vs. 10.1%;
Table 1).
Epileptologists prescribed fewer AEDs than other physi-
cians (median of 2 versus a median of 5, p < 0.001) – this
is likely related to a much shorter period the patients were
treated by epileptologists vs. other physicians (6 vs. 22
years). We noted differences in medication side effects
leading to medication discontinuation (newer AEDs were
discontinued less frequently than old AEDs; p = 0.043).
Further, we noted minor differences in types of AED used
between the epileptologists and other physicians. Epilep-
tologists used pregabalin (8.4% v 2.2%; p = 0.002) more
frequently, while the other physicians used bromides
(4.5% v 0.6%; p = 0.045), carbamazepine (55.1 v 10.7; p
= 0.001), carbamazepine extended release (17.4 v 11.8; p
= 0.001), chronic benzodiazepines (25.8% v 12.4%; p <
0.001), felbamate (16.3 v 7.9; p = 0.013) and zonisamide
(10.1 v 8.4; p < 0.001) more frequently. It is noted that
there were fifteen comparisons for this analysis, so accept-
ing the significance level of 0.05 might lead to an increase
in Type I error (false positive finding). Using the Bonfer-
roni correction, a conservative significance level that pre-
serves the Type I error would be 0.0033.
We noted that the proportion of seizure-free patients
increased significantly over the time the patients received
treatment in the epilepsy center, from 10.1% to 26.4% (pPage 3 of 6
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quency decreased from 4 seizures per month to 1 seizure
per month (p < 0.001).
We recognize the particular problems that can arise when
analyzing skewed data using a parametric statistical
model. To enable the use of parametric models, we com-
puted the change in seizure frequency as the primary out-
come variable, rather than an absolute seizure number,
since this was more likely to be normally distributed. Sec-
ond, we removed outliers to avoid significantly impacting
the model by including extreme values. To validate our
assumptions, we checked the distribution of residuals
from the general linear model and found them to be close
to normally distributed, suggesting transformation of the
data was not strictly necessary. Thus, using a generalized
linear model to determine whether the epileptologist(s)
prescribing newer vs. older AEDs might account for the
change observed when care was transitioned from the
generalist, we found that whether older or newer, or a
combination of older and newer drugs, was given, it did
not significantly change the seizure frequency (p = 0.305).
Discussion
In this retrospective study we evaluated the contribution of
medication choice and physician specialty on seizure control
in a group of patients with medication-resistant epilepsy. We
found that patients treated by epileptologists fared better
than when they were previously treated by other neurolo-
gists, and that the improved seizure control was not related
to whether newer AEDs were prescribed in preference to
older AEDs. In other words, we postulate that patients owe
improved seizure control to epileptologists' better ability to
refine treatment vis-à-vis other neurologists.
Table 1: Demographic and clinical characteristics of patients included in the study.
Age in years (median, range) 43 (21–83)
Female (%) 54.5
Black (%) 14.0
Age at the seizure onset in years (median, range) 10 (0–81)
Epilepsy duration in years (median, range) 30.5 (2–66)
Epilepsy type
Generalized, including symptomatic generalized epilepsy (%) 34.8
Focal onset (%) 57.3
Unknown (%) 7.9
Duration of treatment by an epilepsy specialist in years (median, range) 6 (1–29)
Duration of treatment by physician(s) other than epilepsy specialist in years (median, range) 22 (1–62)
Average number of seizures/month prior to treatment by an epilepsy specialist (median, range) 4 (0–3000)
Average number of seizures/month over the last 12 months (median, range; the "seizure freedom" variable) 1 (0–300)
Seizure-free at the time of the initial visit (%) 10.1
Seizure-free at the time of the last visit (%) 26.4
Psychiatric comorbidities (%) 33.7




Cerebral palsy/mental retardation/developmental delay 46.6
Other neurologic comorbidities 30.3
MRI ever done (%) 74.7
DEXA done (%) 28.7
Receiving bone replacement therapy (%) 39.9
Patients with falls (%) 7.3
Patients with fractures (%) 6.7Page 4 of 6
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should invest in specialty care or general care.[1,2] In the
neurology setting, several examples of improved out-
comes are noted when neurologists manage patients with
acute or chronic conditions when compared to generalists
(same relationship is noted between neurology sub-spe-
cialists and generalists). For example, implementation of
a general neurology care line has led to decreased hospital
admissions and improved quality of the provided services
when compared to other non-specialty care for neurolog-
ical patients.[14] In neurology, subspecialty care may lead
to further improvement. Overall, the most frequently
noted positive influence of subspecialty care on outcomes
is for acute stroke patients. In one study, neurologists
treating patients with acute stroke attained better out-
comes when compared to internists or family practition-
ers, even after adjusting for patient age, co-morbidity, and
other characteristics. The increased costs associated with
providing subspecialty care were justified, in the authors'
opinion, since subspecialty-treated patients had lower
mortality and higher chance of discharge to rehabilitation
facilities possibly decreasing the long-term cost (not
measured in the study). Better outcomes were thought to
be possibly related to specialized training, improved abil-
ity to identify stroke mechanisms, and provision of more
targeted care.[8] Multiple studies have confirmed these
findings, and the fact that stroke units manned by stroke
specialists achieve better treatment outcomes when com-
pared to patients not treated in stroke units is not a sur-
prise.[15] Similarly, the recently created Parkinson's
Disease Research Education and Clinical Centers
(PADRECC) expect better outcomes in patients with Par-
kinson's disease who are treated in centers specializing in
the management of patients with movement disorders as
similar programs in geriatrics and mental illness have
already led to improved outcomes for patients cared for
by geriatricians and psychiatrists, respectively.[16]
The data on the effectiveness of neurologists overall and
epileptologists in particular in improving non-surgical
outcomes of patients with epilepsy is limited. Further, a
recent study showed that about 35% of non-institutional-
ized patients with the diagnosis of epilepsy are not
actively treated by neurologists or epilepsy specialists.[17]
This underscores the importance of examining whether
the care provided by epilepsy specialists over other physi-
cians provides epilepsy patients with incremental benefit.
Further, one large study conducted in the United King-
dom surveyed patients' perceptions of the care available
for epilepsy. Although satisfaction was overall high, there
was a perceived lack of interface between general and epi-
lepsy care; establishment of epilepsy care centers, in order
to provide improved care to the epilepsy patients, was sug-
gested.[18] Finally, an extensive review of nursing litera-
ture did not find any evidence that specialist epilepsy
nurses improved outcomes for epilepsy patients, and a
recent Cochrane review did not find any peer reviewed
studies evaluating whether there was any relationship
between the quality of care provided by epileptologists vs.
general neurologists or general practitioners. [19,20]
In terms of quality of care in epilepsy, one study found
that epileptologists better recognize epilepsy syndrome(s)
than other physicians, and are able to simplify medication
schedules while their patients overall achieve better sei-
zure control.[9] Our study confirms that long-term care by
an epileptologist improves seizure control in many
patients, including patients with multiple handicaps.
Another study evaluated the patterns of patient referral to
the epilepsy centers and found that only 27% were
referred to the epilepsy centers by general neurologists,
while all other patients were referred by non-neurologists;
41% of the patients wished they were referred earlier.
Unfortunately, these authors did not assess the outcomes
of treatment after the transition of care.[11] Finally, we
recently conducted a small study on a convenience sample
of epilepsy patients who transitioned their care from gen-
eral neurology practices to an epilepsy center due to insur-
ance changes. We observed significant improvements in
seizure-freedom (48.5% vs. 69.1%; p = 0.03) between the
time of the first and last visit, suggestive of improved out-
comes after receiving care in an epilepsy center.[10]
Although improvements in outcomes were noted, the rea-
sons for the improvements were not investigated. There-
fore, it appears that the current study is the first to focus
on the benefits of being treated for epilepsy by an epilep-
tologist when compared to a non-epileptologist, account-
ing for the possible treatment differences in various
environments. We show that epileptologists provide sig-
nificant benefits to patients with medication-resistant epi-
lepsy beyond what can be offered by non-epileptologists.
This suggests that patients with medication-resistant epi-
lepsy may benefit from earlier referral to an epilepsy
center for further diagnosis and management as improved
seizure control is associated with better quality of life and
better ability to integrate with the society. [21-24]
Several limitations of the study should be noted. The ret-
rospective design of the study introduces potential biases,
including patient selection and possibly incorrect ascer-
tainment of clinical data such as seizure frequency. It is
also possible that the initial seizure frequency may be
exaggerated since a sudden or transient escalation in sei-
zure frequency may have been a reason for patient referral
to an epilepsy specialist. We attempted to minimize this
by averaging the initial seizure frequency over three
months, a time 3–6 times longer than our current waiting
time for patients to see an epilepsy specialist. Further,
ascertainment of seizures in non-institutionalized
patients may be subjected to another patient-related bias
– these patients may not report their seizures as such
reporting may lead to driving and other restrictions withPage 5 of 6
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life.[22,25] Lack of data that would potentially explain the
reasons for improved seizure control in patients treated by
epileptologists limits interpretation; we did not collect
data on re-classification of seizure diagnosis or whether
syndrome-specific AEDs were used or not by general neu-
rologists (e.g., valproic acid in patients with IGE). Further
prospective studies addressing these issues will be needed.
In summary, our study shows that patients with medica-
tion-resistant epilepsy may benefit from evaluation and
treatment by an epileptologist, with the primary benefit
being reduced seizure frequency. This retrospective study
should stimulate prospective evaluations focusing on the
quality and cost of care in patients with epilepsy and
investigations of whether the higher costs of specialty epi-
lepsy care are offset and justified by improvements in
quality of life.
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